KAI1和CD_(44)v6蛋白在肝癌中的表达及其预后研究  

Expression of KAI1 protein and its relationship with CD44v6 in HCC and prognosis study

作　　者：郑伟红[1] 杨卫兵[1] 符常波[1] 李兴睿[1] 杨志芳[1] 易继林[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院甲乳外科,武汉430030

出　　处：《中国现代医学杂志》2007年第20期2481-2484,共4页China Journal of Modern Medicine

摘　　要：目的探讨KAI1和CD44v6蛋白在肝癌中的表达及其与肝癌患者临床病理特征之关系及预后。方法应用免疫组织化学S-P法,检测87例肝癌组织中KAI1及CD44v6蛋白的表达,用Cox风险回归模型评价肝癌患者预后独立因素。结果KAI1蛋白与肿瘤的分化程度,远处转移相关,而CD44v6仅与远处转移相关。肝癌中KAI1和CD44v6的表达无相关性。Cox模型分析显示影响肝癌患者预后因素是KAI1表达,远处转移和CS分级。结论KAI1和CD44v6的异常表达参与了肝癌的转移过程;KAI1表达,远处转移,CS分级是肝癌患者预后的独立因素。[Objective] To investigate the expressions of KAI1 and CD44v6 in human hepatocellular carcinoma （HCC） and the relationship between expressions of them and their clinicopathological features ＆ prognosis. [Methods] The expressions of KAI1 and CD44v6 in 87 samples with HCC were detected by S-P immunohistochemistry. [Results] Expression of KAI1 had correlation with metastasis of HCC, and was strongly associated with differentiation of HCC cells. The expression of CD44v6 in HCC had correlation with metastasis. There was no difference between the expression of KAI1 and CD44v6. Cox model analysis showed that the prognostic factors were KAI1 expression, metastasis and CS staging system. [Conclusion] The abnormal expression of KAI1 and CD44v6 participate metastasis of HCC, KAI1 expression, metastasis and CS staging system can be used to independently predict the prognosis of HCC patients.

关 键 词：KAI1 CD44V6 肝癌 肿瘤转移 

分 类 号：R735.7[医药卫生—肿瘤]